Members of the Scientific Advisory Council


Terry Sharrer

Former Curator of Health Sciences of the National Museum of American History Smithsonian Institution

With a PhD in history from the University of Maryland, and a long career at the National Museum of American History, where he interviewed more than two dozen Nobel laureates, collaborated with the Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, the National Institutes of Health,  and built the premier museum collection of molecular medicine. He would say that life is full of surprises.  After retiring from the Smithsonian, he worked on medical innovation for the Inova Health System and Cancer Treatment Centers of America, and may still have a last act to play with researchers who hope to grow transplantable, artificial organs.  A life of surprises, indeed.

Lorie Karnath

Mrs. Lorie Karnath

Co-Founder of The Explorers Museum

Avid explorer, adventurer, and author who has canvased the globe in search of answers to elusive questions. Most recently served three terms as the 37th president of The Explorers Club—only the second woman in the club’s 108-year history to be elected.

Robin (2)

Emanuel Petricoin

University Professor for the School of Systems Biology at George Mason University and Co-Director Center for Applied Proteomics and Molecular Medicine

Dr. Petricoin co-leads the Center of Applied Proteomics and Molecular Medicine (CAPMM) with Dr. Lance Liotta. The CAPMM team’s mission is to conduct research on mechanisms of disease related to protein structure and function, and to translate the findings to patient benefit though early stage disease diagnoses, prevention, personalized precision medicine, and the discovery of novel therapies. The scientists of the Center comprise a multidisciplinary team of physicians, molecular biologists, medical technology experts, bioengineer, nanotechnology experts, and biochemists. The CAPMM team invents new technology to address questions in medical science that could not be answered in the past. We use our novel technologies to conduct research on disease mechanisms. The CAPMM has invented, developed, published, and patented transformative technologies and research discoveries in medical fields under the Center mission.


Robin Felder

Professor of Pathology for the University of Virginia

Dr. Felder has focused his research in pathogenesis of essential hypertension and salt sensitivity – We employ a multidimensional approach to the study of high blood pressure including the  molecular genetics,  biochemical techniques, in-vitro, and in-vivo studies in humans.    Through the use of in vivo pharmacologic experiments we have demonstrated that a defect in an intracellular enzyme results in the inability to normally excrete sodium, thus leading to elevated blood pressure. Our studies extend to  the use of human subjects in the Clinical Research Center to determine the effect of pharmacologic intervention in normal and pathologic states.

Robin (1)

Peter Hotez

Dean of National School of Tropical Medicine for Baylor College of Medicine, Professor in Department of Pediatrics of Molecular Virology & Microbiology, Co-Head for the Section of Pediatric Tropical Medicine, and Health Policy Scholar

Current projects include, Human Hookworm VaccineDevelopment of a vaccine for the more than 400 million people suffering from hookworm infection in the world today. Vaccine currently in phase 1 clinical trials in Brazil and Gabon. Dr. Hotez’s second project is Schistosomiasis Vaccine Schistosomiasis afflicts over 200 million people around the globe and is the deadliest disease among the seven most prevalent NTDs, killing an estimated 280,000 people annually. Our vaccine is entering phase 1 clinical trials.



Michael Blaese

Dr. Blaese was the American Geneticist noted for his innovative work in gene therapy and applied genomics. In the early 1980s Blaese and his colleagues hit upon the idea that defective genes could be changed, and subsequently devised a strategy to deliver engineered viruses to correct such defective genes. In 1990 the team had their first success when they treated a young girl with adenosine deaminase (ADA). This breakthrough led them to apply the same principles of gene therapy to other metabolic disorders and cancer.



Jose Marie Griffiths

President at Dakota State University

Dr. Griffiths has spent over 30 years in research, teaching, public service, corporate leadership, economic development, and higher education administration. She has used her knowledge and expertise in computational science and technology to advance projects and endeavors across all of these fields. She has conducted ground-breaking work in meta-data and return-on-investment analysis of “big data” information systems, including multiple approaches to cost-benefit assessment; the influences of the digital revolution on the conduct of research, technology transfer, and economic development; and developing and implementing innovative and successful models for higher education/government/corporate multi-disciplinary partnerships and collaborations.


© 2020 JASON Learning